Trask Aaron J, Ferrario Carlos M
The Hypertension and Vascular Research Center, Wake Forest University Health Science Center, Winston-Salem, North Carolina 27157, USA.
Cardiovasc Drug Rev. 2007 Summer;25(2):162-74. doi: 10.1111/j.1527-3466.2007.00012.x.
Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.
在过去几十年中，心血管领域取得了许多进展。其中包括肾素-血管紧张素系统（RAS）的七肽成员血管紧张素-（1-7）[Ang-（1-7）]迄今为止所取得的进展。该肽对诸如心律失常、心力衰竭、高血压、肾病、先兆子痫甚至癌症等病理生理过程的有益作用不断被发现。这篇综述涵盖了Ang-（1-7）的药理学，并阐述了该肽作为一种治疗剂针对心血管连续统内外病理过程的潜力。
